🔬✨ Overall Response Rate 50%! Chinese Research Entity’s Solid Tumor CAR-T Hits Colorectal Cancer

🔬✨ Overall Response Rate 50%! Chinese Research Entity’s Solid Tumor CAR-T Hits Colorectal Cancer

#Solidtumor

In the journey to conquer cancer, a significant breakthrough is stirring! Shanghai Sundise Biotech has successfully developed the first candidate product GCC19CART, based on its independently developed CoupledCAR® platform technology. This innovative autologous #CART therapy product is specifically designed to target solid tumors of recurrent/refractory metastatic colorectal cancer (R/R mCRC). Let’s delve into this milestone achievement together!

#GCC19CART

On April 19, 2022, Shanghai Sundise Biotech announced that its solid tumor CAR-T product GCC19CART had been granted Fast Track designation by the U.S. Food and Drug Administration (#FDA). This news implies that the development of GCC19CART will be accelerated, bringing hope and new treatment options to more colorectal cancer patients.

#NCCN

So, what is recurrent/refractory colorectal cancer? According to the definition by the National Comprehensive Cancer Network (NCCN), it refers to patients who have undergone multiple rounds of conventional treatment without success or have developed metastases, facing extremely limited treatment options. Current statistics show that the survival rate and objective response rate of such patients are extremely low, urgently requiring more effective treatment methods.

#colorectalcancer

GCC19CART has demonstrated significant clinical activity by targeting and eliminating cancer cells expressing the colorectal cancer tumor marker GCC. According to publicly available data, GCC is widely expressed in colorectal cancer and is highly expressed in metastatic colorectal cancer cells, making it an ideal target for treatment. Preliminary clinical trial results indicate that GCC19CART exhibits significant objective response rates and acceptable safety profiles in refractory metastatic colorectal cancer, bringing new hope to patients.

#ORR 50%

A multicenter Phase I dose-escalation clinical trial conducted in China showed that the objective response rate in the medium-dose group (2×106 CAR-T/kg) reached an encouraging 50%. This suggests that GCC19CART may become an important choice for treating recurrent/refractory colorectal cancer, bringing longer survival and better quality of life to patients.

#Hope

Colorectal cancer is a disease that seriously threatens human health, and the successful development and clinical trial results of GCC19CART bring us new hope. Let’s look forward together to the early clinical application of this innovative treatment method, bringing light to more patients in need of help!

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: 137 1795 9070
Email: [email protected]

💪💊 #ColorectalCancer #CARTtherapy #MedicalInnovation